摘要:
The present invention discloses a modified exendin or pharmaceutically acceptable salts thereof, wherein the modified exendin comprises an amino acid sequence having at least 90% sequence identity to SEQ ID No. 17 and the amino acid sequence has a higher stability than the non-modified exendin of SEQ ID No. 4. These compounds are useful in treating type 2 diabetes as GLP-1 receptor agonists.
摘要翻译:本发明公开了一种修饰的毒蜥外泌肽或其药学上可接受的盐,其中所述修饰的毒蜥外泌肽包含与SEQ ID No.17具有至少90%序列同一性的氨基酸序列,并且所述氨基酸序列具有比未修饰的毒蜥外泌肽更高的稳定性 这些化合物可用于治疗2型糖尿病作为GLP-1受体激动剂。
摘要:
Novel exendins with modifications at one or more of following positions: 2, 14, 27 or 28 and polyethylene glycol derivatives thereof are provided. These compounds are useful in treating type 2 diabetes as GLP-1 receptor agonists.
摘要:
The present invention discloses a modified exendin or pharmaceutically acceptable salts thereof, wherein the modified exendin comprises an amino acid sequence having at least 90% sequence identity to SEQ ID No. 17 and the amino acid sequence has a higher stability than the non-modified exendin of SEQ ID No. 4. These compounds are useful in treating type 2 diabetes as GLP-1 receptor agonists.
摘要翻译:本发明公开了一种修饰的毒蜥外泌肽或其药学上可接受的盐,其中所述修饰的毒蜥外泌肽包含与SEQ ID No.17具有至少90%序列同一性的氨基酸序列,并且所述氨基酸序列具有比未修饰的毒蜥外泌肽更高的稳定性 这些化合物可用于治疗2型糖尿病作为GLP-1受体激动剂。
摘要:
Novel exendins with modifications at one or more of following positions: 2, 14, 27 or 28 and polyethylene glycol derivatives thereof are provided. These compounds are useful in treating type 2 diabetes as GLP-1 receptor agonists.
摘要:
What is provided is EPO mimetic peptide derivatives defined as formula (I) and their pharmaceutical salts, the preparation thereof, wherein R1, R2, R3, R4, R5, n1, n2 are defined as described in description. A composition comprising of an EPO mimetic peptide derivative defined as formula (I) and its pharmaceutical salt. The uses of the derivatives and their pharmaceutical salts, as well as the uses of the compositions described above in treatment of diseases characterized by a deficiency of EPO or a low or defective red blood cell population. R1—R2—(CH2)n1—R3—(CH2)n2—R4—R5 (I)
摘要:
What is provided is EPO mimetic peptide derivatives defined as formula (I) and their pharmaceutical salts, the preparation thereof, wherein R1, R2, R3, R4, R5, n1, n2 are defined as described in description. A composition comprising of an EPO mimetic peptide derivative defined as formula (I) and its pharmaceutical salt. The uses of the derivatives and their pharmaceutical salts, as well as the uses of the compositions described above in treatment of diseases characterized by a deficiency of EPO or a low or defective red blood cell population. R1—R2—(CH2)n1—R3—(CH2)n2—R4—R5 (I)
摘要:
This invention discloses GLP-1 analogues and their pharmaceutical salts, wherein the GLP-1 analogue comprises an amino acid sequence of general formula (I), wherein Lys represents a modified lysine with a lipophilic acid. The GLP-1 analogues provided by this invention have the function of human GLP-1, and a longer half-life in vivo compared with the human GLP-1. Uses of such compounds and compositions include treating non-insulin-dependent diabetes, insulin-dependent diabetes, and obesity. (I) X1-X2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12- X13-X14-Glu-X16-X17-Ala-X19-X20-X21-Phe-Ile-X24- Trp-Leu-X27-X28-X29-X30-X31-X32-X33-X34-X35-X36- X37-X38-X39-Lys
摘要:
This invention discloses GLP-1 analogues and their pharmaceutical salts, wherein the GLP-1 analogue comprises an amino acid sequence of general formula (I), wherein Lys represents a modified lysine with a lipophilic acid. The GLP-1 analogues provided by this invention have the function of human GLP-1, and a longer half-life in vivo compared with the human GLP-1. Uses of such compounds and compositions include treating non-insulin-dependent diabetes, insulin-dependent diabetes, and obesity. X1-X2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12-X13-X14-Glu-X16-X17-Ala-X19-X20-X21-Phe-Ile-X24-Trp-Leu-X27-X28-X29-X30-X31-X32-X33-X34-X35-X36-X37-X38-X39-Lys Formula (I)—SEQ ID NO: 238
摘要翻译:本发明公开了GLP-1类似物及其药物盐,其中GLP-1类似物包含通式(I)的氨基酸序列,其中Lys表示具有亲脂性酸的经修饰的赖氨酸。 本发明提供的GLP-1类似物具有人GLP-1的功能,与人GLP-1相比体内的半衰期更长。 这些化合物和组合物的用途包括治疗非胰岛素依赖性糖尿病,胰岛素依赖型糖尿病和肥胖症。 X1-X2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12-X13-X14-Glu-X16-X17-Ala-X19-X20-X21-Phe-Ile-X24-Trp- Leu-X27-X28-X29-X30-X31-X32-X33-X34-X35-X36-X37-X38-X39-LysFormula(I)-SEQ ID NO:238
摘要:
This invention discloses GLP-1 analogues and their pharmaceutical salts, wherein the GLP-1 analogue comprises an amino acid sequence of general formula (I), wherein Lys represents a modified lysine with a lipophilic acid. The GLP-1 analogues provided by this invention have the function of human GLP-1, and a longer half-life in vivo compared with the human GLP-1. Uses of such compounds and compositions include treating non-insulin-dependent diabetes, insulin-dependent diabetes, and obesity. (I) X1-X2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12- X13-X14-Glu-X16-X17-Ala-X19-X20-X21-Phe-Ile-X24-Trp- Leu-X27-X28-X29-X30-X31-X32-X33-X34-X35-X36-X37-X38-X39- Lys
摘要:
A state retention power gated cell includes a logic cell arranged in two or more rows. The logic cell has an active layer including at least a first well and a second well disposed in first and second rows, respectively. In a normal operation mode, the first well is powered with a first bias voltage, the second well is powered with a second bias voltage, the first power supply line is powered with VDDC, and the second power supply line is powered with VDD. In a standby mode, the first well preferably is powered down, the second well is powered with the second bias voltage, the first power supply line is powered with VDDC, and the second power supply line is powered down.